Dual-specificity kinase DYRK3 phosphorylates p62 at the Thr-269 residue and promotes melanoma progression
Journal of Biological Chemistry · 2024-04 · 300 (4) · 107206
DOI: 10.1016/j.jbc.2024.107206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2024-04. Verfasst von Ye Hyung Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea. Hauptthemen laut MEDLINE: Melanoma, Protein Serine-Threonine Kinases, Protein-Tyrosine Kinases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Melanoma is a type of skin cancer that originates in melanin-producing melanocytes. It is considered a multifactorial disease caused by both genetic and environmental factors, such as UV radiation. Dual-specificity tyrosine-phosphorylation-regulated kinase (DYRK) phosphorylates many substrates involved in signaling pathways, cell survival, cell cycle control, differentiation, and neuronal development. However, little is known about the cellular function of DYRK3, one of the five members of the DYRK family. Interestingly, it was observed that the expression of DYRK3, as well as p62 (a multifunctional signaling protein), is highly enhanced in most melanoma cell lines. This study aimed to investigate whether DYRK3 interacts with p62, and how this affects melanoma progression, particularly in melanoma cell lines. We found that DYRK3 directly phosphorylates p62 at the Ser-207 and Thr-269 residue. Phosphorylation at Thr-269 of p62 by DYRK3 increased the interaction of p62 with tumor necrosis factor receptor-associated factor 6 (TRAF6), an already known activator of mammalian target of rapamycin complex 1 (mTORC1) in the mTOR-involved signaling pathways. Moreover, the phosphorylation of p62 at Thr-269 promoted the activation of mTORC1. We also found that DYRK3-mediated phosphorylation of p62 at Thr-269 enhanced the growth of melanoma cell lines and melanoma progression. Conversely, DYRK3 knockdown or blockade of p62-T269 phosphorylation inhibited melanoma growth, colony formation, and cell migration. In conclusion, we demonstrated that DYRK3 phosphorylates p62, positively modulating the p62-TRAF6-mTORC1 pathway in melanoma cells. This finding suggests that DYRK3 suppression may be a novel therapy for preventing melanoma progression by regulating the mTORC1 pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea.
- Department of Bioengineering, College of Engineering, Hanyang University, Seoul, South Korea.
- Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea. Electronic address: kchung@yonsei.ac.kr.
Förderung
- National Research Foundation of Korea
Zitieren
APA
Lee, Y. H., Yoon, A. R., Yun, C. O., & Chung, K. C. (2024). Dual-specificity kinase DYRK3 phosphorylates p62 at the Thr-269 residue and promotes melanoma progression. Journal of Biological Chemistry, 300(4), 107206. https://doi.org/10.1016/j.jbc.2024.107206
Vancouver
Lee YH, Yoon AR, Yun CO, Chung KC. Dual-specificity kinase DYRK3 phosphorylates p62 at the Thr-269 residue and promotes melanoma progression. Journal of Biological Chemistry. 2024;300(4):107206. doi:10.1016/j.jbc.2024.107206
BibTeX
@article{Lee2024,
author = {Lee, Ye Hyung and Yoon, A-Rum and Yun, Chae-Ok and Chung, Kwang Chul},
title = {Dual-specificity kinase DYRK3 phosphorylates p62 at the Thr-269 residue and promotes melanoma progression},
journal = {Journal of Biological Chemistry},
year = {2024},
volume = {300},
number = {4},
pages = {107206},
doi = {10.1016/j.jbc.2024.107206}
}
EUVIMED